IP Library › Granted Patent US 12,221,486
Granted Patent B2
US 12,221,486 · App. 17/363,749 · Granted Feb 11, 2025

Caninized human antibodies to human IL-4R alpha

Inventors: Mohamad Morsey (Omaha, NE); Yuanzheng Zhang (Edison, NJ)
Assignee: INTERVET INC.
C07K16/2866A61P17/00C07K2317/21C07K2317/24C07K2317/33C07K2317/34C07K2317/524C07K2317/526C07K2317/53C07K2317/71C07K2317/73C07K2317/732C07K2317/76
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,221,486
App. No.
17/363,749
Granted
Feb 11, 2025
Kind
B2
Abstract

The present invention provides caninized human anti-human IL-4Rα antibodies that have specific sequences and a high binding affinity for canine IL-4Rα. The invention also relates to use of these antibodies in the treatment of dogs against atopic dermatitis.

Claims (20)

1. A nucleic acid that encodes a canine kappa light chain of a caninized antibody that specifically binds interleukin-4 receptor alpha (IL-4Rα); wherein the canine kappa light chain comprises three light chain complementary determining regions (CDRs): CDR light 1 (CDRL1), CDR light 2 (CDRL2), and CDR light 3 (CDRL3); and

(a) wherein CDRL1 comprises the amino acid sequence of SEQ ID NO: 43;

(b) wherein CDRL2 comprises the amino acid sequence comprising SEQ ID NO: 44; and

(c) wherein CDRL3 comprises the amino acid sequence of SEQ ID NO: 45.

2. The nucleic acid of claim 1 , wherein the kappa light chain comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 34, SEQ ID NO: 36, and SEQ ID NO: 38.

3. The nucleic acid of claim 2 , wherein the kappa light chain comprises a nucleotide sequence selected from the group consisting of SEQ ID NO: 33, SEQ ID NO: 35, and SEQ ID NO: 37.

4. A nucleic acid that encodes a canine IgG heavy chain of a caninized antibody that specifically binds interleukin-4 receptor alpha (IL-4Rα); wherein the canine IgG heavy chain comprises three heavy chain CDRs: CDR heavy 1 (CDRH1), CDR heavy 2 (CDRH2) and CDR heavy 3 (CDRH3); and

(a) wherein CDRH1 comprises the amino acid sequence of SEQ ID NO: 46;

(b) wherein CDRH2 comprises the amino acid sequence of SEQ ID NO: 47; and

(c) wherein CDRH3 comprises the amino acid sequence of SEQ ID NO: 48.

5. The nucleic acid of claim 4 , wherein the canine IgG heavy chain comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 28, SEQ ID NO: 30, and SEQ ID NO: 32.

6. The nucleic acid of claim 5 , that comprises a nucleotide sequence selected from the group consisting of SEQ ID NO: 27, SEQ ID NO: 29, and SEQ ID NO: 31.

7. An expression vector comprising the nucleic acid of claim 2 .

8. An expression vector comprising the nucleic acid of claim 1 .

9. A host cell comprising the expression vector of claim 8 .

10. A host cell comprising the expression vector of claim 7 .

11. An expression vector comprising the nucleic acid of claim 5 .

12. An expression vector comprising the nucleic acid of claim 4 .

13. A host cell comprising the expression vector of claim 12 .

14. A host cell comprising the expression vector of claim 11 .

Assignments (2)
CHANGE OF ADDRESS Recorded Sep 26, 2023
From: INTERVET INC.
To: INTERVET INC.
Reel/Frame 065028/0818 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 30, 2021
From: MORSEY, MOHAMAD; ZHANG, YUANZHENG
To: INTERVET INC.
Reel/Frame 056721/0053 →
Continuity (4)
Division 16061712
Provisional Application 62401368 · Sep 29, 2016
Provisional Application 62269486 · Dec 18, 2015
Related Publication 20220056143A1 · Feb 24, 2022
References Cited (151)
US 6005079A · Casterman et al. · 1999 [cited by applicant]
US 6703360B2 · McCall et al. · 2004 [cited by applicant]
US 6808710B1 · Wood et al. · 2004 [cited by applicant]
US 6936704B1 · Freeman et al. · 2005 [cited by applicant]
US 7038013B2 · Freeman et al. · 2006 [cited by applicant]
US 7101550B2 · Wood et al. · 2006 [cited by applicant]
US 7105328B2 · Wood et al. · 2006 [cited by applicant]
US 7186809B2 · Pluenneke · 2007 [cited by applicant]
US 7208579B2 · Watson et al. · 2007 [cited by applicant]
US 7261890B2 · Krah, III et al. · 2007 [cited by applicant]
US 7432059B2 · Freeman et al. · 2008 [cited by applicant]
US 7595048B2 · Honjo et al. · 2009 [cited by applicant]
US 7635757B2 · Freeman et al. · 2009 [cited by applicant]
US 7638492B2 · Wood et al. · 2009 [cited by applicant]
US 7700301B2 · Wood et al. · 2010 [cited by applicant]
US 7709214B2 · Freeman et al. · 2010 [cited by applicant]
US 7722868B2 · Freeman et al. · 2010 [cited by applicant]
US 7807158B2 · Endl et al. · 2010 [cited by applicant]
US 8008449B2 · Korman et al. · 2011 [cited by applicant]
US 8337842B2 · Hansen · 2012 [cited by applicant]
US 8354509B2 · Carven et al. · 2013 [cited by applicant]
US 8569460B2 · Hansen · 2013 [cited by applicant]
US 8652470B2 · Hansen · 2014 [cited by applicant]
US 8735553B1 · Li et al. · 2014 [cited by applicant]
US 8791242B2 · Mattson et al. · 2014 [cited by applicant]
US 8877189B2 · Eriksson et al. · 2014 [cited by applicant]
US 9067999B1 · Honjo et al. · 2015 [cited by applicant]
US 9580496B2 · Gearing · 2017 [cited by applicant]
US 9616120B2 · Hansen · 2017 [cited by applicant]
US 9790280B2 · Rue et al. · 2017 [cited by applicant]
US 20020165135A1 · McCall et al. · 2002 [cited by applicant]
US 20070003546A1 · Lazar et al. · 2007 [cited by applicant]
US 20070037210A1 · Chemtob et al. · 2007 [cited by applicant]
US 20070148164A1 · Farrington et al. · 2007 [cited by applicant]
US 20100266617A1 · Carven et al. · 2010 [cited by applicant]
US 20110318373A1 · Sasikumar et al. · 2011 [cited by applicant]
US 20120039906A1 · Olive · 2012 [cited by applicant]
US 20140356372A1 · Stahl et al. · 2014 [cited by applicant]
US 20150017176A1 · Kostic et al. · 2015 [cited by applicant]
US 20160311902A1 · Morsey et al. · 2016 [cited by applicant]
US 20160333096A1 · Morsey et al. · 2016 [cited by applicant]
EP 1537878B1 · 2005 [cited by applicant]
EP 1836226B1 · 2011 [cited by applicant]
EP 2705057B1 · 2016 [cited by applicant]
JP 2014140982 · 2016 [cited by applicant]
WO 9404678A1 · 1994 [cited by applicant]
WO 9425591A1 · 1994 [cited by applicant]
WO 1999051642A1 · 1999 [cited by applicant]
WO 2003042402A2 · 2003 [cited by applicant]
WO 2003060080A2 · 2003 [cited by applicant]
WO 2005032399A2 · 2005 [cited by applicant]
WO 2008083174A2 · 2008 [cited by applicant]
WO 2008156712A1 · 2008 [cited by applicant]
WO 2010070346A2 · 2010 [cited by applicant]
WO 2010110838A2 · 2010 [cited by applicant]
WO 2010117448A2 · 2010 [cited by applicant]
WO 2010117760A2 · 2010 [cited by applicant]
WO 2012135408A1 · 2012 [cited by applicant]
WO 2012153121A1 · 2012 [cited by applicant]
WO 2012153122A1 · 2012 [cited by applicant]
WO 2012153123A1 · 2012 [cited by applicant]
WO 2012153126A1 · 2012 [cited by applicant]
WO 2013030568A1 · 2013 [cited by applicant]
WO 2013034900A1 · 2013 [cited by applicant]
WO 2013063186A2 · 2013 [cited by applicant]
WO 2013124666A1 · 2013 [cited by applicant]
WO 2014197470A1 · 2014 [cited by applicant]
WO 2015091910A2 · 2015 [cited by applicant]
WO 2015091911A2 · 2015 [cited by applicant]
WO 2015091914A2 · 2015 [cited by applicant]
WO 2016050721A1 · 2015 [cited by applicant]
WO 2016006241A1 · 2016 [cited by applicant]
WO 2016156588A1 · 2016 [cited by applicant]
U.S. Appl. No. 16/061,712, filed Jun. 13, 2018. [cited by applicant]
Al-Lazikani, Standard Conformations for the Canonical Structures of Immunoglobulins, J. Mol. Biol., 1997, 927-948, 273. [cited by applicant]
Alegre, A non-activating “humanized” anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo, Transplantation, 1994, 1537-1543, 57. [cited by applicant]
Amgen vs. Sanofi and Regeneron, Case 17-1480, Document 176, filed Feb. 6, 2018, United States Court of Appeals for the Federal Circuit, Response to Petition for Rehearing En Banc, 27 pages. [cited by applicant]
Atherton, MJ et al., Cancer immunology and canine malignant melanoma: A comparative review, Veterinary Immunology and Immunopathology, 2016, pp. 15-26, 169. [cited by applicant]
Barber et al., Restoring function in exhausted CD8 T cells during chronic viral infection, Nature, 2006, pp. 682-687, vol. 439. [cited by applicant]
Baudino et al., Crucial Role of aspartic acid at position 265 in the CH2 domain for muri e IgG2a and IgG2b Fc-assiciated effector functions, J. Immunology, 2008, pp. 6664-6669, vol. 181. [cited by applicant]
Bendig, Mary E., humanization of Rodent Monoclonal Antibodies by CDR Grafting, Methods: A companion to methods in Enzymology, 1993, 83-93, 8. [cited by applicant]
Bergeron et al., Comparative functional characterization of canine IgG subclasses, Veterinary Immunology and Immunopathology, 2014, pp. 31-41, 157. [cited by applicant]
Berglund, L et al., The epitope space of the human proteome, Protein Science, 2008, pp. 606-613, 17. [cited by applicant]
Brown, Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production, J. Immunol., 2003, pp. 1257-1266, vol. 170. [cited by applicant]
Chan et al., Therapeutic antibodies for autoimmunity and inflammation, The Journal of Immunology, 2010, pp. 301-316, 10-5, WO. [cited by applicant]
Chothia and Lesk et al., Canonical Structures for the Hypervariable Regions of Immunoglobins, J. Mol. Biol., 1987, 901-917, 196. [cited by applicant]
Chothia et al., Conformations of immunoglobin hypervariable regions, Nature, 1989, 877-883, 342. [cited by applicant]
Cobbold, et al., The immunology of companion animals: reagents and therapeutic strategies with potential veterinary and human clinical applications, Immunology Today, 1994, pp. 347-353, 15-8. [cited by applicant]
Colman, Effects of amino acid sequence changes on antibody-antigen interactions, Research Immunology, 1994, 33-36, 145. [cited by applicant]
Dong et al., Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion, Nature Medicine, 2002, pp. 793-800, vol. 8(8). [cited by applicant]
Dorai, H et al., Aglycosylated chimeric mouse/human IgG1 antibody retains some effector function, Hybridoma, 1991, pp. 211-217, 10(2). [cited by applicant]
Esch, et al., Programmed Death 1-Mediated T Cell Exhaustion during Visceral Leishmaniasis Impairs Phagocyte Functioni, The Journal of Immunology, 2013, pp. 5542-5550, 191, WO. [cited by applicant]
Galizzi et al., Molucular cloning of a cDNA encoding the human interleukin 4 receptor, International Immunology, 1990, 669-675, 2(7). [cited by applicant]
Gearing, DP et al., A fully caninised anti-NGF monoclonal antibody for pain relief in dogs, BMC Veterinary Research, 2013, pp. 1-11, vol. 9 (226), WO. [cited by applicant]
Geczy, T et al., Molecular basis for failure of “Atypical” C1 domain of Vav1 to bind diacylglycerol/phorbol ester, The Journal of Biological Chemistry, 2012, pp. 13137-13158, 287(16). [cited by applicant]
GenBank accession No. AAL35301.1, amino acid sequence of IgGA heavy chain, 1 page. [cited by applicant]
GenBank accession No. AAL35302.1, amino acid sequence of IgGB heavy chain, 1 page. [cited by applicant]
GenBank accession No. AAL35303.1, amino acid sequence of IgGC heavy chain, 1 page. [cited by applicant]
GenBank accession No. AAL35304.1, amino acid sequence of IgGD heavy chain, 1 page. [cited by applicant]
GenBank accession No. ABY55569.1, lambda light chain amino acid sequence, 1 page. [cited by applicant]
GenBank accession No. ABY57289.1, kappa light chain amino acid sequence, 1 page. [cited by applicant]
GenBank accession No. NP000409.1, mature predicted canine IL-4 receptor alpha chain protein sequence shares 65% identity with human IL-4 receptor alpha chain, 1 page. [cited by applicant]
GenBank accession No. NP999505.1, mature predicted canine IL-4 receptor alpha chain protein sequence shares 70% identity with swine IL-4 receptor alpha chain, 1 page. [cited by applicant]
GenBank accession No. XP54077.3, an 823 amino acids, including a 25 amino acid leader sequence, 1 page. [cited by applicant]
GenBank accession XM547077.4, Full length canine IL-4 receptor alpha chain sequence, 1 page. [cited by applicant]
Harskamp et al., Immunology of Atopic Dermatitis: Novel Insights into Mechanisms and Immunomodulatory Therapies, Seminars in Cutaneous Medicine and Surgery, 2013, 132-139, 32. [cited by applicant]
Hutchins, Improved bio distribution, tumor targeting and reduced immunogenicity in mice with a gamma 4 variant of CAMPATH-1H, Proc. Natl. Acad. Sci. USA, 1995, pp. 11980-11984, 92. [cited by applicant]
Ikebuchi et al., Blockade of bovine PD-1 increases T cell funtion and inhibits bovine leukemia virus expression in B cells in vitro, Veterinary Research, 2013, 1-15, 44-59. [cited by applicant]
International Search Report for PCT/EP2015/081138 mailed May 4, 2017, 22 pages. [cited by applicant]
Iwai, Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade, Proc. Natl. Acad. Sci. USA, 2002, pp. 12293-12297, vol. 99. [cited by applicant]
Jackson, et al., In Vitro Antibody Maturation, Improvement of a High Affinity, Neutralizing Antibody Against IL-1Beta, The Journal of Immunology, 1995, pp. 3310-3319, 154, WO. [cited by applicant]
Kabat, The Structural Basis of Antibody Complementarity, Adv. Prot. Chem., 1978, 1-75, 32. [cited by applicant]
Kabat, Unusual Distributions of Amino Acids in Complementarity-determining (Hypervriable) Segment of Heavy and Light Chains of Immunoglobulins and Their Possible Roles in Specificity of Antibody-combining Sites, J. Biol… [cited by applicant]
Khantasup, K et al., Design and generation of humanized single-chain Fv derived from mouse hybridoma for potential targeting application, Monoclonal antibodies, 2015, pp. 404-417, 34(6). [cited by applicant]
Lin, The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors, Proc. Natl. Acad. Sci. USA, 2008, pp. 3011-3016, vol. 105. [cited by applicant]
Lund et al., J. Immunol., J. Immunol., 1996, pp. 4963-4969, 157. [cited by applicant]
Lyford-Pike, et al., Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma, Cancer Research, 2012, pp. 1733-1741, 73-6, WO. [cited by applicant]
Malajian et al., New pathogenic and therapeutic paradigms in atopic dermatitis, Cytokine, 2015, 311-318, 73. [cited by applicant]
McDermott, et al., PD-1 as a potential target in cancer therapy, Cancer Medicine, 2013, pp. 662-673, WO. [cited by applicant]
McEarchern, Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities, Blood, 2007, 1185-1192, 109. [cited by applicant]
Mimura, Y et al., Glycosylation engineering of therapeutic IgG antibodies: challenges for the safety, functionality and efficacy, Protein Cell, 2018, pp. 47-62, 9(1). [cited by applicant]
Minty et al., Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses, Nature, 1993, 248-250, 362. [cited by applicant]
Mosley et al., The Murine Interleukin-4 Receptor: Molecular Cloning and Characterization of Secreted and Membrane Bound Forms, Cell, 1989, 335-348, 59(2). [cited by applicant]
Muyldermans, Recognition of antigens by single-domain antibody fragments: the superfluous luxury of paired domains, Trends Biochem. Sci., 2001, 230-235, 26. [cited by applicant]
National Service Foundation Award Abstract #1262435, ABI Innovation: Predicting the combined impact of multiple mutations on protein functional adaptation, 2012, 2 pages. [cited by applicant]
NCBI Reference Sequence: XP_543338.3, Sep. 24, 2013, XP055179334, retrieved from Internet: URL:http://www.ncbi.nlm.nih.gov/protein/XP_543338. [cited by applicant]
Nomi et al., Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer, Clinical Cancer Research, 2007, pp. 2151-2157, vol. 13. [cited by applicant]
Nuttall et al., Canine Atopic Dermatitis—what have we learned?, Veterinary Record, 2013, 201-207, 172(8). [cited by applicant]
Okazaki, PD-1 and PD-1 ligands: from discovery to clinical application, Int. Immunol., 2007, pp. 813-824, vol. 19. [cited by applicant]
Paul, We, Fundamental Immunology, Fundamental Immunolgy, third edition, 1993, 292-295, Third Edition. [cited by applicant]
Rahman et al., The Pathology and Immunology of Atopic Dermatitis, Inflammation & Allergy—Drug Targets, 2011, 486-496, 10. [cited by applicant]
Regeneron Pharmaceuticals, Inc., Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis, 71st Annual Meeting of the American Academy of Dermatology, Mar. … [cited by applicant]
Reichmann, Single domain antibodies: comparison of camel VH and camelised human VH domains, J. Immunol. Methods, 1999, 25-38, 231. [cited by applicant]
Roguin, LP et al., Monoclonal antibodies inducing conformational changes on the antigen molecule, Scandinaavian Journal of Immunology, 2003, pp. 387-394, 58. [cited by applicant]
Rudikoff, S et al., Single amino acid substitution altering antigen-binding specificity, PNAS, 1982, pp. 1979-1983, 79. [cited by applicant]
Sazinsky, Aglycosylated immunoglobin G1 variants productively engage activating Fc receptors, Proc. Natl. Acad. Sci., 2008, 20167-20172, 105. [cited by applicant]
Shields, High Resolution Mapping of the Binding Site on Human IgG1 for FcyRI, FcyRII, FcyRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FeyR, J. of Biol. Chem., 2001, 6591-6604, 276-9. [cited by applicant]
Strome et al., B7-H1 Blockade Augments Adoptive T-Cell Immunotherapy for Squamous Cell Cancinoma, Cancer Research, 2003, pp. 6501-6505, vol. 63. [cited by applicant]
Tang et al., Cloning and characterization of cDNAs encoding four different canine immunoglobulin Y chains, Veterinary Immunology and Immunopathology, 2001, pp. 259-270, 80. [cited by applicant]
Tao, MH et al., Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region, The Journal of Immunology, 1989, pp. 2595-2601, 143(8). [cited by applicant]
Thompson et al., PD-1 Is Expressed by Tumor-Infiltrating Immune Cells and Is Associated with Poor Outcome for Patients with Renal Cell Carcinoma, Clinical Cancer Research, 2007, pp. 1757-1761, vol. 15. [cited by applicant]
Thompson et al., Tumor B7-H1 Is Associated with Poor Prognosis in Renal Cell Carcinoma Patients with Long-Term Follow-up, Cancer Res., 2006, pp. 3381-3385, vol. 66. [cited by applicant]
Tsushima et al., Predominant expression of B7-H1 and its immunoregulatory roles in oral squamous cell carcinoma, Oral Oncol., 2006, pp. 268-274, vol. 42. [cited by applicant]
Tzartos, SJ, Epitope mapping by antibody competition, Methods in Molecular Biology, 1996, pp. 55-66, 66. [cited by applicant]
Van Der Kaaij et al., Molecular cloning and sequencing of the cDNA for dog interleukin-4, Immunogenetics, 1999, 142-143, 49. [cited by applicant]
Vatrella, Dupilumab: a novel treatement for asthma, Jornal of Asthma and Allergy, 2014, 123-130, 7. [cited by applicant]
Wintterle et al., Expression of the B7-Related Molecule B7-H1 by Glioma Cells: A Potential Mechanism of Immune Paralysis, Cancer Res., 2003, pp. 7462-7467, vol. 63. [cited by applicant]
Wong, et al., Structural Requirements for a Specificity Switch and for Maintenance of Affinity Using Mutational Analysis of a Phage-Displayed Anti-Arsonate Antibody of Fab Heavy Chain First Complementarity-Determining R… [cited by applicant]
Yang et al., Canine Interleukin-13: Molecular Cloning of Full-Length cDNA and Expression of Biologically Active Recombinant Protein, Journal of Interferon and Cytokine Research, 2000, 779-785, 20. [cited by applicant]
Yokota et al., Isolation and characterization of a human interleukin cDNA clone, homologous to mouse B-cell stimulatory factor 1, that expresses B-cell- and T-cell-stimulating activities, Proc. Natl. Acad. Sci. USA, 198… [cited by applicant]
Zhang et al., Structural and Functional Analysis of the Costimulatory Receptor Programmed Death-1, Immunity, 2004, pp. 337-347, vol. 20. [cited by applicant]